Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Viridian Therapeutics Q2 2024 Adj EPS $(1.02) Misses $(0.89) Estimate, Sales $72.00K Miss $86.15K Estimate

Author: Benzinga Newsdesk | August 08, 2024 08:29am
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.89) by 14.61 percent. The company reported quarterly sales of $72.00 thousand which missed the analyst consensus estimate of $86.15 thousand by 16.43 percent. This is the same as the same period last year.

Posted In: VRDN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist